Grant: China-Canada Joint Health Research Initiative
McMaster University
$143,475.00
Characterization of AKF-PD-mediated protection of diabetic nephropathy in db/db mice
EF 2009-10
Résumé
Approximately 8.8% of Canadians and 5% of Chinese have diabetes, with one-third of them developing diabetic nephropathy. A large number of these patients will have their disease progress towards end-stage renal disease (ESRD). Currently, we cannot control the progression of diabetic nephropathy towards ESRD, nor can we effectively treat ESRD. Therefore, diabetic nephropathy is a major and serious complication of diabetes and there is an urgent need to develop drugs to treat or effectively control the disease. Professor Tao's research group in China has recently invented a very promising drug, called AKF-PD (also known as Fluorofenidone). In their research involving mice with diabetic nephropathy, AKF-PD has been shown to effectively control the progression of diabetic nephropathy. In the current research proposal, Dr. Tao's research group in China and Dr. Tang's laboratory in Canada will work together to investigate 1) whether AKF-PD can prevent diabetic nephropathy when the drug is given to diabetic mice before developing diabetic nephropathy, 2) whether AFK-PD can effectively control further progression of diabetic nephropathy towards ESRD at time when the disease is already at an advance stage, 3) how AKF-PD prevents or cures diabetic nephropathy. This information will be essential in our effort to prevent diabetic nephropathy and to control the disease even at advance stages. As more than 3 million Canadians suffers from diabetes and its complications, this research offers a promising hope to find a novel therapy to control diabetic nephropathy.
Programme
China-Canada Joint Health Research Initiative
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
203977
Name
Tang Damu
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
National Natural Science Foundation of China (Haidian, Beijing)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
China-Canada Joint Health Research Initiative - Grants Program
Projecttitle
Characterization of AKF-PD-mediated protection of diabetic nephropathy in db/db mice
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$143,475
Cihrequipment2
$0
Programname2
China-Canada Joint Health Research Initiative
Keyworddelim
Apoptosis; Cell Biology/Signal Transduction; Db/Db Mice; Diabetes; Diabetic Nephropathy; Sirna
Abstract
Approximately 8.8% of Canadians and 5% of Chinese have diabetes, with one-third of them developing diabetic nephropathy. A large number of these patients will have their disease progress towards end-stage renal disease (ESRD). Currently, we cannot control the progression of diabetic nephropathy towards ESRD, nor can we effectively treat ESRD. Therefore, diabetic nephropathy is a major and serious complication of diabetes and there is an urgent need to develop drugs to treat or effectively control the disease. Professor Tao's research group in China has recently invented a very promising drug, called AKF-PD (also known as Fluorofenidone). In their research involving mice with diabetic nephropathy, AKF-PD has been shown to effectively control the progression of diabetic nephropathy. In the current research proposal, Dr. Tao's research group in China and Dr. Tang's laboratory in Canada will work together to investigate 1) whether AKF-PD can prevent diabetic nephropathy when the drug is given to diabetic mice before developing diabetic nephropathy, 2) whether AFK-PD can effectively control further progression of diabetic nephropathy towards ESRD at time when the disease is already at an advance stage, 3) how AKF-PD prevents or cures diabetic nephropathy. This information will be essential in our effort to prevent diabetic nephropathy and to control the disease even at advance stages. As more than 3 million Canadians suffers from diabetes and its complications, this research offers a promising hope to find a novel therapy to control diabetic nephropathy.
Competitiondate
201003
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tang, Damu; Tao, LIJIAN
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $143,475~ $0~